Entrapment ability and release profile of corticosteroids from starch-based microparticles by Silva, G. A. et al.
Entrapment ability and release profile of corticosteroids
from starch-based microparticles
G. A. Silva,1,2 F. J. Costa,1 N. M. Neves,1,2 O. P. Coutinho,1,3 A. C. P. Dias,3 R. L. Reis1,2
13B’s Research Group—Biomaterials, Biodegradables, Biomimetics, University of Minho, Campus de Gualtar, 4710-057,
Braga, Portugal
2Department of Polymer Engineering, University of Minho, Campus de Azure´m, 4800-058 Guimara˜es, Portugal
3Department of Biology, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal
Received 13 September 2004; revised 2 November 2004; accepted 19 November 2004
Published online 10 March 2005 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/jbm.a.30287
Abstract: We previously described the synthesis of starch-
based microparticles that were shown to be bioactive (when
combined with Bioactive Glass 45S5) and noncytotoxic. To
further assess their potential for biomedical applications
such as controlled release, three corticosteroids with a sim-
ilar basic structure—dexamethasone (DEX), 16-methyl-
prednisonole (MP), and 16-methylprednisolone acetate
(MPA)—were used as models for the entrapment and re-
lease of bioactive agents. DEX, MP, and MPA were en-
trapped into starch-based microparticles at 10% wt/wt of
the starch-based polymer and the loading efﬁciencies, as
well as the release proﬁles, were evaluated. Differences were
found for the loading efﬁciencies of the three corticosteroids,
with DEX and MPA being the most successfully loaded (82
and 84%, respectively), followed by MP (51%). These differ-
ences might be explained based on the differential distribu-
tion of the molecules within the matrix of the microparticles.
Furthermore, a differential burst release was observed in the
ﬁrst 24 h for all corticosteroids with DEX and MP being
more pronounced (around 25%), whereas only 12% of MPA
was released during the same time period. Whereas the
water uptake proﬁle can account for this ﬁrst stage burst
release, the subsequent slower release stage was mainly
attributed to degradation of the microparticle network. Dif-
ferences in the release proﬁles can be explained based on the
structure of the molecule, because MPA, a more bulky and
hydrophobic molecule, is released at a slower rate compared
with DEX and MP. In this work, it is shown that these
carriers were able to sustain a controlled release of the
entrapped corticosteroids over 30 days, which conﬁrms the
potential of these systems to be used as carriers for the
delivery of bioactive agents. © 2005 Wiley Periodicals, Inc.
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INTRODUCTION
Because of the considerable advantage of their clear-
ance from the body after the release of therapeutic
agents, biodegradable polymers are among the most
widely used materials for controlled drug delivery
applications.1 Starch-based polymers have been stud-
ied mainly by Reis et al.2–5 for a wide range of bone-
related applications, ranging from tissue engineering
scaffolds,6–11 to bone cements,12–14 and drug delivery
systems.14–16 These materials display a set of features
that support their potential in the biomedical ﬁeld,
such as natural origin, good mechanical proper-
ties,3,11,17–19 good biological performance,20–25 and the
possibility of tailoring their properties26–29 according
to the foreseen application. Recently, we have de-
scribed the use of a blend of starch and polylactic acid
(SPLA50) to synthesize microparticles (polymer and
composite with Bioactive Glass 45S5) with a deﬁned
size range that were found to be bioactive and noncy-
totoxic.30 A potential application for these developed
microparticles is as carriers for bioactive agents in
controlled release applications.
There are two basic general strategies to develop
polymeric matrices for delivery systems: the use of
hydrophobic matrices that can release encapsulated
drugs as a result of their bioerosion or biodegradation,
or the use of hydrogel matrices, that can swell and
retain large volumes of water, thus allowing diffusion
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of the drug.31 The combination of these two strategies
(by using a blend of hydrophobic-hydrophilic poly-
mers, such as polylactic acid and starch) might allow
for the synthesis of a carrier that combines the best
features of each material. Factors inﬂuencing release
rate include drug molecular size and loading efﬁ-
ciency into the polymer, polymer composition and
molecular weight, and the dimensions, shape, and
crystallinity of the matrix.31,32
Considering all these aspects, the entrapment of
bioactive molecules within starch-based micropar-
ticles and subsequent release proﬁle were evaluated to
assess the potential of these micron-size systems to be
used as carriers for drug delivery. For this purpose,
three different corticosteroids were chosen as model
bioactive agents. Corticosteroids have a widespread
use in clinical practice because of their broad range of
antiinﬂammatory activities; they are used in affections
such as acute respiratory distress, degenerative dis-
eases, as well as immunosuppressors in organ trans-
plantation.33 Dexamethasone (DEX) has a high esti-
mated potency,34 being used for several applications,
in which ocular ones have a major importance. DEX
delivery systems for eye delivery, as well as for pre-
venting stent restenosis, have been documented.34–36
It has also been widely used in in vitro cell culture
where differentiation of bone marrow cells into the
osteoblastic lineage is to be achieved.37 Methylpred-
nisolone is used similarly to DEX, ﬁnding applications
in endocrine and rheumatic disorders as adjunctive
therapy for short-term administration, collagen dis-
eases during exacerbation or as maintenance therapy,
and also in several dermatological diseases (psoriasis,
dermatitis, Stevens-Johnson syndrome).
In the present work, we describe the ability of
starch-based microparticles to act as carriers for drug
delivery applications, by means of entrapping and
evaluating the release proﬁles of three corticosteroids,




A blend of starch and polylactic acid (PLA) herein re-
ferred to as SPLA50 (50% cornstarch, 50% PLA, by weight)
was used as the raw material. The PLA used in this blend
was PLA 4040, 94% L-lactide from Cargill-Dow (Minneapo-
lis, MN), and the blended material was supplied by Nova-
mont (Novara, Italy). More information on this material can
be found elsewhere.7 Methylene chloride (Sigma, St Louis,
MO) and polyvinyl alcohol 87–89% hydrolyzed (Aldrich,
Milwaukee, WI) were used for the production of the micro-
particles. DEX 98% [high-performance liquid chromatog-
raphy (HPLC) grade; Sigma], MP 99%, and MPA 99.3%
(both in-house produced) were used as the bioactive mole-
cules for entrapment and release studies. All other chemicals
used were reagent grade (Panreac, Barcelona, Spain) except
methanol, which was HPLC grade (Riedel-de-Hae¨n, Sigma/
Aldrich, Seetze, Germany).
Synthesis of starch-based microparticles loaded
with corticosteroids
The synthesis methodology for SPLA50 microparticles
was as described previously.30 Brieﬂy, SPLA50 was mixed
with the steroid (10% weight of polymer) and dissolved in
methylene chloride. This solution was then emulsiﬁed with
a stirring 0.5% polyvinyl alcohol solution for up to 4 h in a
top stirrer at a speed of 660 rpm/min. The microparticles
were then washed and separated from the reaction solution
by ﬁltration. The reaction solution was stored for quantiﬁ-
cation of the nonloaded corticosteroid. Steroid-loaded mi-
croparticles were freeze-dried and stored in a desiccator
until further use. This procedure was performed separately
for each of the corticosteroids used, namely, DEX, MP, and
MPA. Values of 2.5, 5, and 10% wt/wt (DEX/polymer) were
tested to determine the ratio of bioactive agent to polymer
that achieved the highest encapsulation efﬁciency. At least
three independent experiments were performed for each of
the corticosteroids with reproducible results.
Physicochemical characterization of SPLA50
microparticles
Starch-based microparticles—unloaded, steroid-loaded,
and after a 30-day release period—were gold coated and
analyzed by scanning electron microscopy using a Leica
Cambridge S-360 model (Cambridge, UK) to assess morpho-
logical features and differences between conditions.
To assess changes in the microparticles between pre- and
postrelease, Fourier transformed infrared attenuated reﬂec-
tion (FTIR-ATR) was performed. Spectra were recorded at
least at 32 scans with a resolution of 2 cm1 in an FTIR
spectrophotometer (Perkin-Elmer 1600 series). All the sam-
ples were analyzed using a single reﬂection ATR system
(MKII Golden Gate™, Specac) with a diamond crystal (angle
of incidence 45°; active sampling area 0.8 0.8 mm; depth of
penetration 20 m).
Degradation and water uptake of SPLA50
microparticles
Measuring the weight loss of the microparticles assessed
the degradation behavior, and the water uptake behavior
measured by the capability of the microparticles to incorpo-
rate water in their matrix (swelling), both parameters being
studied over a period of 90 days. For this, SPLA50 micro-
particles were weighted and immersed in a phosphate-
buffer saline (PBS) solution at physiological pH (pH 7.4) at a
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ratio of 1 mg/1 mL, and placed into a water bath at 37°C
with constant agitation (60 rpm).
After predetermined time periods (up to 30 days for water
uptake, 90 days for weight loss), the vials containing the
immersed microparticles were centrifuged at low speed for
particle deposition and the supernatant was removed for
further measurements of degradation products. The remain-
ing wet microparticles were weighted for water uptake mea-
surements. Water uptake was determined using the follow-
ing equation38:
% Water uptake  mwmi/mi]  100,
where mi is the initial weight and mw is the wet weight of the
sample. After each time period, the samples were dried at
37°C and the ﬁnal mass of the samples weighted to deter-
mine the weight loss according to the following equation38:
% Weight loss  mfmi/mi]  100,
where mf is the ﬁnal weight of the dry sample and mi is the
initial weight of the sample. Triplicates were performed for
each sample at each time period and the results are shown as
mean  standard deviation.
Determination of DEX, MP, and MPA loading
efficiency and release profile
Loading efficiency
The loading efﬁciency for the different steroids was de-
termined by measuring the amount of corticosteroid remain-
ing in the reaction medium (unloaded) where the micropar-
ticles were synthesized. Aliquots of 1 mL of the reaction
medium were taken and the amount of DEX, MP, and MPA
present in each sample was measured using HPLC as de-
scribed in the section HPLC Analysis. The results were
obtained from three independent experiments run in dupli-
cate with reproducible results and the mean value is re-
ported.
The loading efﬁciency was calculated from the following
formula:
Loading efficiency (%) 	 (CSi  CSr)/CSi  100%
where CSi is the initial amount of corticosteroid to be loaded
and CSr the amount of corticosteroid remaining in the reac-
tion medium (unloaded), where microparticles were synthe-
sized.
In vitro release studies
In vitro release studies were conducted in PBS, 0.1M, pH
7.4. Preweighted corticosteroid-loaded microparticles were
immersed in sterile PBS at a ratio of 5 mg/mL under mild
agitating conditions, at 37°C. At predetermined time points,
PBS aliquots were sampled for further quantiﬁcation of the
released corticosteroid. The results were obtained from two
independent experiments run in duplicate with reproduc-
ible results and the mean value is reported.
HPLC analysis
Samples were extracted three times with a mixture of
hexane and ethyl acetate (1:1), to selectively remove the
steroids. The extracts were combined and evaporated under
a nitrogen ﬂow. The residues were redissolved in methanol
and subjected to analysis by HPLC.
The HPLC system consisted of an auto-injector Midas
Injector Spark, and a Beckman System Gold Solvent Module
126 coupled to a Detector Module 166. The separation of the
samples was performed in a PurospherStar RP-18e column
(250  4.5 mm, 5-m particle size; Merck, Germany), using
methanol and water as solvents. The following gradient was
used: 50% methanol for 10 min, 30% methanol–70% water
for 25 min. The ﬂow rate was 1 mL/min and the detection
wavelength used was 254 nm. Quantiﬁcation of DEX, MP,
and MPA was performed using the internal standard
method using Triamcinolone (Lederle, New York, NY) as
the reference compound.
RESULTS AND DISCUSSION
Synthesis of starch-based microparticles with
encapsulated DEX, MP, and MPA
Figures 1 and 2 show representative scanning
electron microscope images of the unloaded and cor-
ticosteroid-loaded microparticles, respectively. The
synthesis method yielded corticosteroid-loadedmicro-
particles with morphologies similar to unloaded mi-
croparticles (Fig. 1). Therefore, the entrapment of the
steroids does not seem to produce signiﬁcant changes
in the morphology of the microparticles.
For both unloaded and loaded microparticles, two
different surfaces can be found, namely, micropar-
ticles with a rougher surface [Fig. 2(A)] and micropar-
ticles with a smoother surface [Fig. 2(C)]. For the
rougher-surface microparticles, a porous surface is ob-
Figure 1. Representative image of unloaded SPLA50 mi-
croparticles showing the two different morphologies ob-
served in each batch of microparticles, one displaying a
rough surface and the other a smoother surface.
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servable at higher magniﬁcations [Fig. 2(B)], which
greatly enhances the surface area of the microparticle,
compared with the surface of a smoother micropar-
ticle [Fig. 2(D)], in which no pores are visible.
Staining with iodine solution was performed to dis-
tinguish between starch and PLA phases, because io-
dine is known to bind to starch, yielding a dark blue
color. Iodine staining revealed that the rough surface
is due to the starch phase (stained as dark blue areas),
and the smooth surface is due to the PLA phase (re-
sults not shown). This morphological feature, com-
bined with the hydrophobic PLA and hydrophilic
starch natures, can greatly inﬂuence the properties of
the microparticles in terms of degradation and release
proﬁles.
Water uptake and degradation profiles of the
microparticles
The release of a drug from a matrix is primarily
controlled by diffusion of the drug through the poly-
mer due to its swelling in aqueous medium, and the
dissolution rate of the drug, erosion of the polymer
being an additional but nonetheless very important
factor.39 For biodegradable polymers, it is essential to
recognize that degradation is a chemical process,
whereas erosion is a physical phenomenon dependent
on dissolution and diffusion process.39 In this way,
knowledge of the water uptake capability and degra-
dation of polymeric materials is of great importance in
studies regarding their use for controlled release ap-
plications. For SPLA50 microparticles, the hydration
and weight loss proﬁles are shown in Figures 3 and 4,
respectively.
The establishment of the water uptake proﬁle might
give insight into the release mechanism because, in the
Figure 2. Morphology of the corticosteroid-loaded microparticles. In (A), the particle presents a rough surface, with
apparent porosity [(B), detail of surface]; in (C) and (D), images of a microparticle displaying a smoother surface. Both
morphologies are representative of the microparticles with different loaded corticosteroids.
Figure 3. Water uptake proﬁle of SPLA50 microparticles as
determined by immersion in a PBS solution for up to 30 days
(n 	 9).
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case of polymers, drug diffusion is primarily con-
trolled by swelling of the polymer matrix. In the
present case, SPLA50 microparticles have the ability to
swell to values as high as 400% of its weight, after 12 h
of soaking, reaching equilibrium after 1 week in PBS
solution, with a value around 300% (Fig. 3). After the
initial release stage controlled by swelling of the ma-
trix, subsequent release is primarily controlled by deg-
radation of the polymer (chemical process).31 As so,
monitoring the weight loss up to 90 days assessed the
degradation of SPLA50 microparticles.
The weight loss proﬁle of the microparticles in Fig-
ure 4 can be described by a reduced initial weight loss
until 48 h, followed by a period spanning from 48 to
500 h during which about 20% of weight is lost. Then
a reduced decrease in weight is observed up to 90
days.
The ﬁrst step in the degradation of the micropar-
ticles occurs mainly through scission of small-size
starch chains into oligosaccharides, as assessed by the
appearance of reducing sugars in solution (data not
shown), up to 500 h. The rate of degradation then
decreases, because the cleavage of larger starch chains
is to occur, this being coupled to the eventually slower
degradation of the PLA phase. Further details on the
degradation mechanisms of starch-based biomaterials
can be found elsewhere.40–42
Entrapment efficiency
The entrapment/loading efﬁciency was determined
by measuring the amount of corticosteroid remaining
on the reaction media after the synthesis of the corti-
costeroid-loaded microparticles. Using HPLC to ana-
lyze aliquots of the reaction media (where corticoste-
roid-loaded microparticles were synthesized), it was
possible to quantify for unloaded corticosteroid. This
value was then subtracted from the initial amount of
corticosteroid to be loaded, enabling the efﬁciency of
drug loading to be obtained (through the formula
described in the section Loading Efﬁciency in Materi-
als and Methods).
To optimize the loading, we studied whether vary-
ing the percentage of drug to be encapsulated would
lead to a variation in the loading efﬁciency, in partic-
ular for DEX. Values of 2.5, 5, and 10% were entrapped
in the microparticles and the loading efﬁciency was
evaluated.
As shown in Figure 5, the higher the initial amount
of drug to be entrapped, the higher the encapsulation
efﬁciency. The highest encapsulation efﬁciency was
attained when 10% wt drug/wt polymer was used,
with a value of 82%. This drug-to-polymer ratio was
chosen for subsequent studies with all the corticoste-
roids.
Table I displays the results of the loading efﬁcien-
cies for each corticosteroid entrapped in the starch-
based microparticles.
From Table I it is clear that DEX and MPA have the
highest encapsulation efﬁciencies, with 82 and 84%,
respectively. The less successful encapsulation was
attained for MP, with 51% loaded into the micropar-
ticles.
The differences in the loading efﬁciencies might be
explained by the structure of the corticosteroids used
(Fig. 6). The basic structure is the same; the only
difference among these molecules is their side groups,
which in DEX is a ﬂuoride atom covalently bonded,
Figure 5. Inﬂuence of DEX initial amount of its loading
efﬁciency. The amount (in grams) of loaded DEX is shown as
labels.
Figure 4. Weight loss proﬁle of SPLA50 microparticles as
determined by immersion in a PBS solution up to 2160 h (90
days) (n 	 9).
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whereas for MPA is the acetate group. As for MP, it
can be considered the basic structure when compared
with the two other molecules.
MPA is a bulkier molecule than DEX or MP. This
bulkiness could facilitate MPA entrapment within the
polymer network that would result in the highest
entrapment efﬁciency (Table I). This result correlates
well with the data obtained from FTIR spectra, in
which the presence of peaks due to drug loading is
evident for DEX (Fig. 7) and also for MPA (Fig. 8),
which can explain the high loading achieved. The
entrapment efﬁciency is lower for MP (51%, Table I),
which by FTIR is shown by the absence of MP char-
acteristic peaks in the spectrum (Fig. 9).
It is visible from the analysis of the FTIR spectra that
for DEX (Fig. 7) and MPA (Fig. 8) there were some
changes in the spectra because of drug loading in the
SPLA50 microparticles, where bands characteristic of
these corticosteroids appeared in the spectra of the
loaded microparticles. This might be because some
drug becomes trapped on/close to the surface of the
polymer matrix during the manufacturing process,
which is in accordance with descriptions in the liter-
ature for other systems.43,44 As for MP (Fig. 9), such
changes were almost absent in the FTIR spectrum of
the loaded microparticles, which as said before, can
explain the lower loading efﬁciency when compared
with DEX and MPA.
For the MPA-loaded microparticles, there was a
reduction in the intensity of the peaks because of the
corticosteroid loading after 30 days of release, which
seems to support the hypothesis that the corticosteroid
trapped at the surface of the microparticles has been
released at the initial stages of release. Regarding
DEX, there was some reduction in the intensity of the
bands because of corticosteroid loading but, neverthe-
less, they remain visible after 30 days of release.
In vitro release profile for DEX, MP, and MPA
The in vitro release proﬁles for DEX (A), MP (B), and
MPA (C) are shown in Figure 10. Analysis of the
TABLE I
Loading Efﬁciencies for the Three Corticosteroids into







16-Methylprednisolone acetate (MPA) 84
aMeasuring the amount of corticosteroid remaining on the
reaction media where the microparticles were formed and
subtracting it from the initial amount of corticosteroid de-
termined the efﬁciency of loading.
Figure 6. Chemical structure for DEX (a), MP (b), and MPA (c).
Figure 7. FTIR spectra of DEX, SPLA50, SPLA50-DEX
loaded, and SPLA50-DEX released microparticles. The black
dots (F) indicate bands present in the microparticles due to
loading of DEX. After 30 days of release, the same bands are
still visible, although a reduction in the intensity is observed.
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release proﬁles indicates that all the corticosteroids are
released with an initial burst phase, followed by a
slower release, typical of a ﬁrst order release kinetics.
This is in accordance with what is described for other
biodegradable polymers.43,45–50 The release proﬁle is
similar for DEX and MP, with 27 and 28% of release
for the ﬁrst 24 h, respectively. This initial burst is then
followed by a slower release until 750 h (30 days), in
which 45% of entrapped DEX and 40% of MP are
released. For MPA, a reduced burst effect is observed
(approximately 12% for the ﬁrst 24 h) compared with
the other two molecules. This initial release is then
followed by a slower release that reaches 30% of the
entrapped MPA by 30 days.
Interestingly, an incomplete release pattern is ob-
served for all corticosteroids, which was also observed
for chitin/poly(lactic-co-glycolic acid) 50:50 micro-
spheres.51 This conﬁrms the potential of this system
for prolonged release of entrapped drugs.
The initial burst phase can be explained by the fact
that the swelling of the material controls the initial
release stages (Fig. 3, water uptake, ﬁrst 12 h), and the
drug is thus released by diffusion through the chan-
nels created by water penetration.39,43,52 At this stage,
degradation/weight loss does not have a signiﬁcant
role in release, because by 24 h only 2% of the weight
is lost (Fig. 4, weight loss). The second, slower release
period can be attributed to the weight loss, because
this phenomenon is only evident after 48 h, in which a
decrease in weight of approximately 20% is observed
until 500 h.
The degradation and corticosteroid release of the
microparticles after 30 days (750 h, Fig. 11) produce
changes in the morphology of the microparticles, ev-
idenced by pores in the surface of the microparticles.
Nevertheless, the microparticle matrix structure is still
maintained, which could account for the drug still
remaining to be released.
The water uptake and weight loss do not account,
however, for the differences observed among the cor-
ticosteroids. Comparing the release proﬁles of MP
[Fig. 10(B)] and MPA [Fig. 10(C)], the differences in
the release proﬁle can be attributed to the structure of
the molecule. Although MPA loading efﬁciency was
higher than the one for MP (Table I), because the
former has a more bulky structure than MP, its release
was expected to be slower than the one for MP. More-
over, the presence of the acetate group in MPA [Fig.
6(C)] renders to this molecule a more hydrophobic
character than MP (considered the basic structure)
[Fig. 6(B)] and thus MPA afﬁnity toward the aqueous
moiety is signiﬁcantly reduced. This same explanation
is applicable to the difference between DEX and MPA
release: although they possess a similar loading efﬁ-
ciency (82 and 84%, respectively), DEX was released
faster and at a higher percentage than MPA, consistent
with a molecule size effect.
When DEX is compared with MP, the difference in
the molecule bulkiness [Fig. 6(A,B)] cannot explain the
differences in the loading efﬁciencies. Furthermore, it
does not seem to have any effect in the release proﬁles.
Importantly, when all the release proﬁles are com-
pared, it should be emphasized that the release into
the medium is inversely correlated with increasing
bulkiness and hydrophobicity of the molecules.
Figure 9. FTIR spectra of MP, SPLA50, SPLA50-MP
loaded, and SPLA50-MP released microparticles. Micropar-
ticles loaded with MP show only minor changes in the
structure compared with unloaded microparticles. The same
observation is evident in the spectrum of microparticles after
30 days of MP release.
Figure 8. FTIR spectra of MPA, SPLA50, SPLA50-MPA
loaded, and SPLA50-MPA released microparticles. The as-
terisks (*) indicate bands present in the microparticles due to
loading with MPA. After release, these bands are almost
absent from the structure of MPA-loaded microparticles.
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CONCLUSIONS
In a previous work,30 by using a blend composed of
starch and polylactic acid (SPLA50), we demonstrated
the ability to form noncytotoxic microparticles within
a deﬁned size range. In this work, we evaluated the
potential of these microparticles for release applica-
tions, by studying the loading and release of cortico-
steroids as model bioactive agents. We successfully
encapsulated DEX and two other corticosteroids—MP
and MPA—with the encapsulation efﬁciencies varying
between 51 and 84%. These differences might be ex-
plained by the structure of the molecules and the
differential distribution of the molecule within the
microparticle structure.
The in vitro release proﬁles showed that these
starch-based systems are capable of sustained release
of the entrapped steroids up to 30 days. The burst
release observed in the ﬁrst 24 h was lower for MPA
when compared with DEX and MP. After this period,
release proceeds for more than 30 days, with DEX and
MP being released up to 45% and MPA up to 30%.
Whereas the water uptake can account for the initial
burst release, degradation can account for the subse-
quent release stage. The remaining loaded corticoste-
roids could be released at later stages, and this release
is likely controlled by the degradation of the micro-
particles.
From these studies we suggest that starch-based
microparticles could be used as carriers for bioactive
agents, and this investigation constitutes a basis for
future entrapment and release studies using other bio-
active agents, such as growth factors (bone morpho-
genetic proteins, vascular endothelial growth factor,
platelet-derived growth factor) or others relevant for
biomedical applications.
Figure 10. Release proﬁles as determined by HPLC quan-
tiﬁcation. (A) DEX, (B) MP, and (C) MPA. The results are
shown as percentage of cumulative release. Right-insert
graphs show the proﬁle for the ﬁrst 12 [MP, (B)] and 24
[DEX, MPA, (A) and (C), respectively] h of release. A burst
release occurs for all steroids, although for MPA this effect is
less pronounced (12%) compared with DEX (27%) and MP
(28%).
Figure 11. Representative images of the morphology of
corticosteroid-loaded SPLA50 microparticles after 30 days of
release in a PBS solution. Some pores are evident in the
surface of the microparticles, but the matrix structure is still
maintained.
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